ETFs Protalix BioTherapeutics, Inc.

PLX

US74365A3095

Pharmaceuticals

Market Closed - NYSE 04:00:00 2026-10-28 pm EDT			5-day change	1st Jan Change
2.590 ^USD	+2.37%		-1.89%	+43.89%

Sep. 16	Protalix BioTherapeutics, Inc. Presents at Morgan Stanley 24th Annual Global Healthcare Conference, Sep-16-2026 01:05 PM
Aug. 12	Protalix BioTherapeutics, Inc., Q2 2026 Earnings Call, Aug 12, 2026

ETFs positioned on Protalix BioTherapeutics, Inc.

Name	YTD change	Weight	AuM
ISHARES MICRO-CAP ETF - USD	+15.05%	0.03%	1,518 M€
FRANKLIN U.S. SMALL CAP MULTIFACTOR INDEX ETF - USD	+13.16%	0.02%	53 M€
VANGUARD RUSSELL 2000 GROWTH ETF - USD	+10.18%	0.01%	1,568 M€
XTRACKERS RUSSELL 2000 UCITS ETF 1C - USD	+18.37%	0.01%	3,050 M€
ISHARES RUSSELL 2000 GROWTH ETF - USD	+10.28%	0.01%	15,028 M€
GLOBAL X RUSSELL 2000 ETF (AU) - AUD	+8.33%	0.01%	18 M€
ISHARES U.S. SMALL CAP INDEX ETF (CAD-HEDGED) - CAD	+12.58%	0.01%	520 M€
ISHARES RUSSELL 2000 VALUE ETF - USD	+18.54%	0.01%	14,676 M€
GLOBAL X RUSSELL 2000 COVERED CALL & GROWTH ETF - USD	+5.98%	0%	9 M€
GLOBAL X RUSSELL 2000 ETF - USD	+13.79%	0%	1,540 M€
ISHARES RUSSELL 2000 ETF - USD	+14.27%	0%	82,179 M€
GLOBAL X RUSSELL 2000 COVERED CALL ETF - USD	+0.39%	0%	1,395 M€
VANGUARD RUSSELL 3000 ETF - USD	+13.11%	0%	4,863 M€
UNLIMITED HFEQ EQUITY LONG/SHORT ETF - USD	+11.12%	0%	19 M€
ISHARES LIFEPATH TARGET DATE 2065 ETF - USD	+13.12%	0%	29 M€
ISHARES LIFEPATH TARGET DATE 2055 ETF - USD	+12.91%	0%	60 M€
ISHARES LIFEPATH TARGET DATE 2060 ETF - USD	+13.22%	0%	41 M€
UNLIMITED HFGM GLOBAL MACRO ETF - USD	+8.77%	0%	162 M€
ISHARES LIFEPATH TARGET DATE 2050 ETF - USD	+12.20%	0%	88 M€
CI GLOBAL CORE PLUS EQUITY ETF - CAD	0.00%	0%	43 M€
ISHARES LIFEPATH TARGET DATE 2045 ETF - USD	+10.99%	0%	91 M€
ISHARES LIFEPATH TARGET DATE 2070 ETF - USD	+13.04%	0%	16 M€
ISHARES LIFEPATH TARGET DATE 2040 ETF - USD	+9.66%	0%	110 M€
ISHARES LIFEPATH TARGET DATE 2035 ETF - USD	+8.12%	0%	113 M€
SIMPLIFY PIPER SANDLER US SMALL-CAP PLUS INCOME ETF - USD	+14.95%	0%	7 M€
BRIDGES CAPITAL TACTICAL ETF - USD	+8.61%	0%	43 M€
CAMBRIA US EW ETF - USD	+11.26%	0%	194 M€
WARREN STREET GLOBAL EQUITY ETF - USD	+13.33%	0%	62 M€
ALPHA ARCHITECT US EQUITY 2 ETF - USD	+12.13%	0%	513 M€
INFRACAP SMALL CAP INCOME ETF - USD	-1.17%	0%	20 M€
SIMPLIFY VOLATILITY PREMIUM ETF - USD	-6.61%	-.--%	538 M€

Protalix BioTherapeutics, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell-based expression system, ProCellEx. In addition, the Company is developing PEGylated uricase, or PRX-115, for the treatment of uncontrolled gout, Long Acting (LA) DNase I, or PRX-119, for the treatment of NETs-related diseases, and other technologies and preclinical assets. Its ProCellEx platform is being used to manufacture both of its approved and marketed products as well as PRX-115 and PRX-119. PRX-115, a plant cell-expressed recombinant PEGylated Uricase (urate oxidase) - a chemically modified enzyme to treat uncontrolled gout. PRX-119 is a plant cell-expressed PEGylated recombinant human DNase I product candidate. Its product includes Elelyso and Elfabrio. Elelyso is an enzyme replacement therapy (ERT) for the treatment of patients with Gaucher disease.

Employees

226

Sector

Pharmaceuticals

More about the company